Phase 2
Completed N=54
fMRI Study Examining Effects of D-cycloserine in Specific Phobia
Phobias
Source: ClinicalTrials.gov NCT00591825 ↗
Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcomePrimary: fMRI Brain Activations During Symptom Provocation — .200; .157; -.013; .036 percent signal change
Summary
The research team hopes to use brain imaging and mental testing to learn more about specific phobias and the treatment of phobia. When given directly prior to therapy sessions, D-cycloserine has been shown to enhance the effects of therapy. This study hopes to identify reasons why D-cycloserine has this effect by measuring brain activity.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY fMRI Brain Activations During Symptom Provocation |
.200; .157; -.013; .036; .012; .021 | — |
| SECONDARY Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) |
51.93; 49; 52.69; 52.93; 34.36; 32.46 | — |
| SECONDARY Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) |
4.93; 4.92; 3.69; 4.14; 34.68; 34.46 | — |
| SECONDARY Cognitive Functioning Measured Using the Iowa Gambling Test |
44.29; 32.62; 28.58; 21.85 | — |
| SECONDARY Cognitive Functioning Measured Using the Wisconsin Card Sorting Task |
13.29; 13.62; 18.23; 15.67 | — |
Eligibility Criteria
Inclusion Criteria
- Right-handed
- Adults between 18 and 55 years of age
- Subjects in the phobic group will additionally meet diagnostic (DSM-IV) criteria for spider phobia.
- Individuals of both genders and all races will be included
Exclusion Criteria
- Women who are breastfeeding or pregnant
- Individuals with medical conditions unsuitable for MR scanning
- Individuals reporting a history of epilepsy or seizures
- Individuals reporting an allergy to cycloserine
- Individuals diagnosed with asthma or who report previous anaphylactic reaction to insect stings/bites, medication, food, or other material and/or event
- Individuals reporting present or past diagnosis of a developmental disorder, neurological disorder, or head injury *Individuals found to have Axis I psychopathology as defined by the DSM-IV (other than spider phobia)
- Individuals currently taking any psychotropic medication
Data sourced from ClinicalTrials.gov (NCT00591825). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.